Market Updates on Drug Manufacturers - Other Equities -- Isis Pharma, Endo Intl., Amarin, United Therapeutics, and POZEN
NEW YORK, July 30, 2015 /PRNewswire/ --
36Equity Research Institute has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Endo International PLC (NASDAQ: ENDP), Amarin Corporation PLC (NASDAQ: AMRN), United Therapeutics Corporation (NASDAQ: UTHR), and POZEN Inc. (NASDAQ: POZN). Free research report on Isis Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ISIS On Wednesday, July 29, 2015, the NASDAQ Composite ended at 5,111.73, up 0.44%, the Dow Jones Industrial Average advanced 0.69%, to finish the day at 17,751.39, and the S&P 500 closed at 2,108.57, up 0.73%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
Isis Pharmaceuticals Inc.'s stock lost 2.48%, to close the day at $53.05. The stock recorded a trading volume of 1.85 million shares, below its three months average volume of 2.37 million shares. Over the last one month and over the past three months, Isis Pharmaceuticals Inc.'s shares have fallen by 5.35% and 10.55%, respectively. Furthermore, the stock has lost 14.08% since the start of this year. The company's shares are trading 12.18% below their 200-day moving average. Additionally, Isis Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 35.93. Sign up and read the free notes on ISIS at:
https://www.EquityResearchInstitute.com/reports?keyword=ISIS
On Wednesday, shares in Endo International PLC recorded a trading volume of 1.31 million shares, lower than their three months average volume of 2.29 million shares. The stock ended the day 1.64% lower at $86.19. Although, Endo International PLC's stock has lost 0.40% in the previous three months, it has advanced 9.95% in the last one month and 19.51% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 3.50% and 7.46%, respectively. Furthermore, shares of Endo International PLC have an RSI of 56.24. The complimentary notes on ENDP can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ENDP
Amarin Corp. PLC's stock gained 1.40%, to close Wednesday's session at $2.18. The stock recorded a trading volume of 0.59 million shares, below its three months average volume of 1.97 million shares. Over the previous three months and since the beginning of 2015, Amarin Corp. PLC's shares have advanced 5.31% and 122.52%, respectively. However, the stock has declined 5.63% in the last one month. The company is trading 28.49% above its 200-day moving average. Furthermore, Amarin Corp. PLC's stock has an RSI of 38.93. Register for free on Equity Research Institute and access the latest research on AMRN at:
https://www.EquityResearchInstitute.com/reports?keyword=AMRN
United Therapeutics Corp.'s stock finished Wednesday's session 0.74% higher at $167.18. A total of 0.71 million shares were traded, which was above its three months average volume of 0.62 million shares. Over the previous three months and since the start of this year, United Therapeutics Corp.'s shares have gained 1.51% and 29.11%, respectively. However, the stock has fallen by 2.09% in the last one month. The company's shares are trading above their 200-day moving average by 7.01%. United Therapeutics Corp.'s stock traded at a PE ratio of 49.46 and has an RSI of 37.76. The complete research on UTHR is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=UTHR
On Wednesday, shares in POZEN Inc. ended the session 3.90% lower at $11.69. The stock reported a trading volume of 0.52 million shares, below its three months average volume of 0.67 million shares. Shares of the company traded at a PE ratio of 23.39. POZEN Inc.'s shares have surged 11.91% in the last one month, 45.28% in the previous three months and 46.19% on YTD basis. The stock is trading 21.23% above its 50-day moving average and 40.29% above its 200-day moving average. Moreover, shares of POZEN Inc. have an RSI of 62.19. Free in-depth research on POZN is available at:
https://www.EquityResearchInstitute.com/reports?keyword=POZN
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article